CD8A and multiple sclerosis: For instance, this is the case in antineutrophil cytoplasmic antibody-associated vasculitis (AAV)41 or in multiple sclerosis treated with ocrelizumab.42 43 Rituximab-treated AAV patients have reduced frequency of CD8+CD45RA+CCR7- T cells (TEMRA) and a reduced production of cytokine/chemokine by CD8+T cells.